Hematology-Oncology Research Faculty
Choose a faculty member to view his or her research profile. Links go to the School of Medicine Research Faculty Directory; use the back button to return to the Hem/Onc division website.
Breast cancer clinical trials for early stage and metastatic breast cancer in selected patient populations.
Malignant hematology (lymphoma, myeloma, leukemia)
Development of clinical trials in breast cancer; cancer immunotherapy; cancer survivorship improvement; cancer and aging.
Clinical research in hematologic malignancies, fertility preservation, and quality improvement.
Novel therapeutic approaches for urologic cancers including prostate, urothelial and kidney cancers.
Cell signaling and survival pathways, genetic alterations, and development of experimental therapeutics; large granular lymphocyte (LGL) leukemia; acute myeloid leukemia (AML); role of polyamines in normal and neoplastic growth in the skin, upper aerodige
Acute Myeloid Leukemia: molecular and cellular biology events which mediate aberrant epigenetic and transcriptional mechanisms during disease establishment and progression
Melanoma, Head and Neck Cancer, Genitourinary malignancies, Drug development, Cancer Immunotherapy
Lung cancer, novel therapies, cancer immunology, and targeted therapy
Clinical trial design and development for novel therapeutics and immunotherapy for the treatment of lung cancer.
Clinical trials in hematologic malignancies, including myelodysplastic syndromes and leukemias with special interest in treating the elderly population, determining optimal combinations and timing of targeted agents in MDS and leukemia, and studying patie
Hematologic malignancies; bone marrow disorders; leukemia; large granular lymphocyte (LGL)
Hemostasis and thrombosis
Clinical trials in hematologic malignancies including leukemias and lymphomas, with special interest in determining optimal combinations and timing of targeted agents in B-cell leukemias and lymphomas.
Dr. Thakur's research activities are focused on 1) developing new and innovative therapeutic approaches to enhance clinical and anti-tumor immune responses; 2) developing novel strategies to attenuate the immune suppressive cellular and humoral factors.
Reduced intensity conditioning use, pre-transplant co-morbidity assessment.
Dr. Williams’ research interests include clinical trials and translational science for mantle cell lymphoma, other non-Hodgkin lymphomas and CLL, with a focus on targeted agents and immuno-therapeutics. He was a co-investigator on three pivotal clinical trials that led to FDA approvals in B-cell lymphoma. The current focus of the Lymphoma and Leukemia Research Team is to improve treatment response and cure via novel combinations of targeted therapeutic agents and to optimize anti-lymphoma immunotherapy.